Background
GlaxoSmithKline (GSK) holds a patent covering the use of carvedilol—sold under the brand name Coreg—for treating congestive heart failure (CHF). When Teva sought FDA approval to sell a generic version, it filed an Abbreviated New Drug Application (ANDA) and used what is known as a “skinny label”: a product label that deliberately omitted the patented CHF indication, listing only two other approved cardiovascular uses for carvedilol that were off-patent.
Under the Hatch-Waxman framework, this type of label carve-out—authorized by Section viii of the statute—is specifically designed to allow generic companies to enter the market without infringing method-of-treatment patents tied to one particular indication. The theory is simple: if the generic’s label does not instruct doctors to use the drug for the patented purpose, the generic should not be liable for inducing infringement of that patent.
Despite Teva’s skinny label, GSK sued for induced infringement under 35 U.S.C. § 271(b), pointing to evidence beyond the label itself—including Teva’s press releases that described carvedilol’s full cardiovascular benefits and market materials that did not limit its utility to only the non-patented indications. A jury found for GSK and returned a $235 million verdict. The district court granted judgment as a matter of law for Teva, and GSK appealed.
The Court’s Holding
The Federal Circuit reversed and reinstated the jury verdict. Writing for the majority, Judge O’Malley held that induced infringement under § 271(b) does not require that the inducement come from the product label alone. Courts must look at the totality of a defendant’s communications and conduct—not just the four corners of the label—to determine whether the defendant actively encouraged or instructed others to practice the patented method.
The majority found that Teva’s press releases announcing FDA approval described carvedilol as a treatment for heart failure broadly, without limiting the announcement to the non-patented uses. The court concluded that a reasonable jury could find these communications were directed at physicians and pharmacists who would understand carvedilol as a treatment for CHF—the patented indication—and that Teva’s conduct therefore encouraged infringement.
Chief Judge Prost dissented sharply, arguing that the majority’s decision effectively nullifies the Section viii skinny label carve-out mechanism Congress established precisely to facilitate generic entry. In her view, the majority’s reading of § 271(b) exposes every generic company that issues ordinary press releases to induced infringement liability whenever any downstream use of its product happens to infringe a patent—even one the generic’s label expressly omits.
Key Takeaways
- A skinny label carving out a patented indication does not, by itself, insulate a generic manufacturer from induced infringement liability—courts will examine all communications and conduct, not just the label.
- Press releases, marketing materials, and other communications that tout a drug’s broad benefits can constitute evidence of inducement even when the product label is narrowly worded.
- Generic companies entering the market under Section viii carve-outs must carefully review all public communications about their products to avoid language that could be read as encouraging use for a patented indication.
- The decision creates significant uncertainty for the Hatch-Waxman skinny label regime and has prompted calls for legislative or regulatory clarification of how § 271(b) applies to ANDA products.
- The Supreme Court denied certiorari, leaving the Federal Circuit’s ruling in place.
Why It Matters
The skinny label carve-out has long been a cornerstone of generic drug competition under Hatch-Waxman. By allowing generic companies to exclude patented indications from their labels, Congress created a pathway for generics to enter the market years earlier on at least some approved uses—lowering drug prices for patients and payers. The GSK v. Teva decision dramatically complicates that pathway.
After this ruling, a generic company faces potential billion-dollar liability not just from its FDA-approved label, but from every press release, investor presentation, and sales communication it issues. Critics—including Chief Judge Prost and numerous amici—warned that the decision will chill generic entry and undermine Hatch-Waxman’s pro-competition goals. Brand-name pharmaceutical companies, on the other hand, welcomed the ruling as strengthening their ability to protect method-of-treatment patents against generics that try to enter the market using only nominally narrow labels. The case remains one of the most consequential and contested Federal Circuit decisions of the 2020s in the pharmaceutical patent space.